Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$240,721
-$108,160 QoQ
Shares Held
1,536
-32.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#1,234
of 1,603 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026EARNED WEALTH ADVISORS, LLC holds $8,347,145 across 10 Drug Manufacturers - General names. NVS ranks #9 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
2,314 | $2,775,481 | |
| 2 | JNJ |
Johnson & Johnson
|
6,284 | $1,595,947 | |
| 3 | ABBV |
AbbVie Inc.
|
5,103 | $1,284,118 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
7,324 | $925,314 | |
| 5 | MRK |
Merck & Co., Inc.
|
3,294 | $423,279 | |
| 6 | PFE |
Pfizer Inc
|
15,837 | $381,354 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
4,515 | $260,154 | |
| 8 | AZN |
Astrazeneca PLC
|
1,288 | $244,230 |
All Filings in NVS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $240,721 | 1,536 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $348,881 | 2,284 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $272,017 | 1,973 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $210,954 | 1,645 | Shares | Sole | 2025-10-22 | |
| No filing history on record for this holder in this stock. | ||||||